دورية أكاديمية
Gastric cancer: Translating novels concepts into clinical practice
| العنوان: | Gastric cancer: Translating novels concepts into clinical practice |
|---|---|
| المؤلفون: | Salati M., Orsi G., Smyth E., Beretta G., De Vita F., Di Bartolomeo M., Fanotto V., Lonardi S., Morano F., Pietrantonio F., Pinto C., Rimassa L., Vasile E., Vivaldi C., Zaniboni A., Ziranu P., Cascinu S. |
| المساهمون: | M. Salati, G. Orsi, E. Smyth, G. Beretta, F. De Vita, M. Di Bartolomeo, V. Fanotto, S. Lonardi, F. Morano, F. Pietrantonio, C. Pinto, L. Rimassa, E. Vasile, C. Vivaldi, A. Zaniboni, P. Ziranu, S. Cascinu |
| بيانات النشر: | W.B. Saunders |
| سنة النشر: | 2019 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Biomarker, Gastric cancer, Genomic tumour profiling, Immunotherapy, Liquid biopsy, Targeted therapy, Animal, Clinical Trials as Topic, Disease Management, Drug Therapy, Combination, Human, Precision Medicine, Stomach Neoplasm, Translational Medical Research, Treatment Outcome, Settore MED/06 - Oncologia Medica |
| الوصف: | The overall 5-year survival of gastric cancer (GC) has change only little in the last decades and it remains the fifth leading cause of cancer-related death worldwide. However, in the past few years a more effective combination chemotherapy has raised the bar of curability of about 10% in resectable disease. Morever, a deeper knowledge of GC biology have unveiled biomarkers to help personalize adjunctive treatments in patients candidate to surgery. Despite a plateau in efficacy of fist-line treatment, incremental survival advantages have been recorded in unresectable advanced disease. The growing number of effective drugs in second and later lines along with a more judicious delivery of cytotoxics and early supportive interventions have enabled more patients to proceed beyond first-line. The continuum of care has become a reality in a considerable proportion of patients that offer opportunities to improve outcomes. Finally, the advent of the immune checkpoint inhibitors has brought great expectations in molecularly-defined subset of patients. This Review summarizes the state-of-the art in the management of GC together with novel concepts that have entered clinical development with the potential of change practice in the foreseeable future. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31445415; info:eu-repo/semantics/altIdentifier/wos/WOS:000488332000002; volume:79; numberofpages:9; journal:CANCER TREATMENT REVIEWS; http://hdl.handle.net/2434/685787Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85070874473 |
| DOI: | 10.1016/j.ctrv.2019.101889 |
| الإتاحة: | https://doi.org/10.1016/j.ctrv.2019.101889Test http://hdl.handle.net/2434/685787Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.97B7F4BC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ctrv.2019.101889 |
|---|